Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of haza
| Business Activity | PASS |
| Debt Ratio (0.35%) | FAIL |
| Cash Ratio (0.00%) | PASS |
| Receivables Ratio (0.07%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-08-06 | 3.13 | Pending | — |
| 2026-05-07 | 2.77 | 2.90 | +4.5% |
| 2026-02-09 | 0.26 | 1.34 | +415.4% |
| 2025-11-06 | 3.91 | 3.96 | +1.1% |
| 2025-08-07 | 3.40 | 3.68 | +8.2% |
| 2025-05-01 | 3.28 | 3.35 | +2.1% |
| 2025-02-05 | 2.99 | 3.43 | +14.7% |
| 2024-11-07 | 3.77 | 3.81 | +1.1% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $4.7B | -$311.0M | $708.0M | $2.2B | $626.0M | -1.11 |
| 2025-12-31 | $5.3B | $382.0M | $1.2B | $2.4B | $662.0M | 1.34 |
| 2025-09-30 | $5.9B | $493.0M | $1.3B | $2.8B | $826.0M | — |
| 2025-06-30 | $5.5B | $574.0M | $1.6B | $2.6B | $979.0M | 2.00 |
| 2025-03-31 | $4.5B | $308.0M | $875.0M | $1.9B | $477.0M | 1.07 |
| 2024-12-31 | — | — | — | — | — | 1.05 |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-05-07 | ROQUE VITOR | Chief Financial Officer | 1,721 | — |
| 2026-04-27 | FELD MICHAEL | Officer | 74 | $11.2K |
| 2026-03-26 | FELD MICHAEL | Officer | 75 | $11.8K |
| 2026-03-16 | MINNIX LANESHA | General Counsel | 7,492 | — |
| 2026-03-02 | SPIKNER PAMELA L | Officer | 931 | — |
| 2026-03-02 | ROQUE VITOR | Chief Financial Officer | 931 | — |
| 2026-02-26 | FELD MICHAEL | Officer | 75 | $13.6K |
| 2026-02-18 | SCOTT BERTRAM LEE | Director | 953 | $174.0K |
| 2026-01-27 | RING TIMOTHY M | Director | 1,098 | — |
| 2026-01-27 | WRIGHT JACQUELINE | Director | 1,098 | — |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Blackrock Inc. | 26.2M | $3.9B | 0.1% |
| Vanguard Capital Management LLC | 18.5M | $2.7B | 0.1% |
| Vanguard Portfolio Management LLC | 15.3M | $2.3B | 0.1% |
| State Street Corporation | 13.8M | $2.0B | 0.1% |
| First Eagle Investment Management, LLC | 11.9M | $1.8B | 0.0% |
| Invesco Ltd. | 10.2M | $1.5B | 0.0% |
| T. Rowe Price Investment Management, Inc. | 9.7M | $1.4B | 0.0% |
| Massachusetts Financial Services Co. | 9.1M | $1.3B | 0.0% |
| Geode Capital Management, LLC | 7.1M | $1.0B | 0.0% |
| Wellington Management Group, LLP | 6.6M | $976.6M | 0.0% |
Buy
Hold
Sell
Strong Sell
$57.1B
1.69
0.285
14
$22.2B
$17.3B
281.0%
2.19
2.35
0.0%
60,000
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-08-06 | $3.13 | Pending | — |
| 2026-05-07 | $2.77 | $2.90 | +4.5% |
| 2026-02-09 | $0.26 | $1.34 | +415.4% |
| 2025-11-06 | $3.91 | $3.96 | +1.1% |
| 2025-08-07 | $3.40 | $3.68 | +8.2% |
| 2025-05-01 | $3.28 | $3.35 | +2.1% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($183.29, 14 analysts) | |||
| 10 | $1,494.30 | +$338.60 (23%) | 1.5R |
| 50 | $7,471.50 | +$1,693.00 (23%) | 1.5R |
| 100 | $14,943.00 | +$3,386.00 (23%) | 1.5R |
| To Fair Value ($270.00) | |||
| 10 | $1,494.30 | +$1,205.70 (81%) | 5.4R |
| 50 | $7,471.50 | +$6,028.50 (81%) | 5.4R |
| 100 | $14,943.00 | +$12,057.00 (81%) | 5.4R |
- No elevated risk flags in current data
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| XLV | 0.531 |
| STE | 0.477 |
| MDT | 0.461 |
| TMO | 0.452 |
| ASH | 0.447 |
| Ticker | Correlation |
|---|---|
| QFBQ.QA | -0.185 |
| LPTVQ | -0.171 |
| OXLCO | -0.137 |
| 9022.T | -0.136 |
| JAZEERA.KW | -0.134 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker’s recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.
Related Tickers
Similar in Healthcare
Also in TE500